CARDIFF ONCOLOGY INC's ticker is CRDF and the CUSIP is 14147L108. A total of 62 filers reported holding CARDIFF ONCOLOGY INC in Q4 2022. The put-call ratio across all filers is 19.84 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $99,227 | -6.7% | 71,386 | -1.4% | 0.00% | – |
| Q2 2023 | $106,407 | -8.4% | 72,386 | +2.8% | 0.00% | – |
| Q1 2023 | $116,198 | +19.6% | 70,423 | +1.5% | 0.00% | – |
| Q4 2022 | $97,138 | -9.2% | 69,384 | 0.0% | 0.00% | – |
| Q3 2022 | $107,000 | -27.2% | 69,384 | +4.2% | 0.00% | – |
| Q2 2022 | $147,000 | -81.3% | 66,592 | -79.0% | 0.00% | – |
| Q1 2022 | $788,000 | -61.3% | 317,858 | -6.3% | 0.00% | – |
| Q4 2021 | $2,038,000 | -5.5% | 339,081 | +4.7% | 0.00% | – |
| Q3 2021 | $2,156,000 | +2.0% | 323,706 | +1.8% | 0.00% | – |
| Q2 2021 | $2,114,000 | +390.5% | 317,845 | +582.1% | 0.00% | – |
| Q1 2021 | $431,000 | -46.2% | 46,597 | +4.7% | 0.00% | – |
| Q4 2020 | $801,000 | +127.6% | 44,520 | +79.4% | 0.00% | – |
| Q3 2020 | $352,000 | +517.5% | 24,817 | +118.8% | 0.00% | – |
| Q2 2020 | $57,000 | – | 11,342 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACT CAPITAL MANAGEMENT, LLC | 120,600 | $299,000 | 0.32% |
| Artal Group S.A. | 750,000 | $1,860,000 | 0.08% |
| Eventide Asset Management | 1,467,922 | $3,640,000 | 0.06% |
| Atom Investors LP | 33,798 | $84,000 | 0.04% |
| XTX Topco Ltd | 25,154 | $62,000 | 0.03% |
| ELKHORN PARTNERS LIMITED PARTNERSHIP | 19,000 | $47,000 | 0.02% |
| Engineers Gate Manager LP | 245,567 | $609,000 | 0.02% |
| GSA CAPITAL PARTNERS LLP | 63,749 | $158,000 | 0.02% |
| KENNEDY CAPITAL MANAGEMENT LLC | 168,902 | $419,000 | 0.01% |
| Walleye Capital LLC | 123,305 | $306,000 | 0.01% |